Semiconductor chips, genes, and stem cells: new wine for new bottles?

Area of Science:

• Biotechnology Law
• Intellectual Property
• Bioeconomics

Background:

• Isolated genes and stem cells face challenges meeting traditional patent requirements like non-obviousness.
• Early semiconductor technology also struggled with patentability criteria in the 1980s.
• The biotechnology industry requires sustained economic growth and funding for research and development.

Purpose of the Study:

• To advocate for sui generis (of its own class) intellectual property protection for isolated bioproducts.
• To draw parallels between the economic and legal challenges of early semiconductor technology and current bioproducts.
• To propose a framework for intellectual property that balances innovation incentives with public access.

Main Methods:

• Analogical reasoning comparing semiconductor and biotechnology industries.
• Analysis of patent law requirements (novelty, non-obviousness, eligible subject matter).
• Economic assessment of research and development funding in emerging technologies.

Main Results:

• Isolated bioproducts, like early semiconductors, do not consistently meet traditional patentability standards.
• High R&D costs necessitate exclusive rights to ensure continued innovation in biotechnology.
• Sui generis protection can incentivize further research and development in the field.

Conclusions:

• A sui generis intellectual property system is proposed for isolated bioproducts to mirror the semiconductor industry's success.
• This protection must incorporate limitations to ensure public access and downstream development.
• Balancing exclusive rights with public domain enrichment is crucial for the biotechnology industry's long-term growth.